A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer

Authors
Category Primary study
JournalMolecular Therapy Oncolytics
Year 2019
This article has no abstract
Epistemonikos ID: 05588b4af2370f8d057149d46ee0ff061bb841ca
First added on: Feb 10, 2025